BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

613 related articles for article (PubMed ID: 28477722)

  • 1. Omalizumab in children with uncontrolled allergic asthma: Review of clinical trial and real-world experience.
    Chipps BE; Lanier B; Milgrom H; Deschildre A; Hedlin G; Szefler SJ; Kattan M; Kianifard F; Ortiz B; Haselkorn T; Iqbal A; Rosén K; Trzaskoma B; Busse WW
    J Allergy Clin Immunol; 2017 May; 139(5):1431-1444. PubMed ID: 28477722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omalizumab: an update on efficacy and safety in moderate-to-severe allergic asthma.
    Chipps BE; Figliomeni M; Spector S
    Allergy Asthma Proc; 2012; 33(5):377-85. PubMed ID: 23026179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The discovery and development of omalizumab for the treatment of asthma.
    Licari A; Marseglia G; Castagnoli R; Marseglia A; Ciprandi G
    Expert Opin Drug Discov; 2015; 10(9):1033-42. PubMed ID: 25979110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and effectiveness of omalizumab in the treatment of childhood asthma.
    Tortajada-Girbés M; Bousquet R; Bosque M; Carrera Martínez JJ; Ibáñez MD; Moreira A; Nieto A; Plaza AM; Rivas C; Requena G; Sánchez-Solis M; Tabar A; Torres-Borrego J; Zapatero L
    Expert Rev Respir Med; 2018 Sep; 12(9):745-754. PubMed ID: 30141696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Omalizumab in Japanese children with severe allergic asthma uncontrolled with standard therapy.
    Odajima H; Ebisawa M; Nagakura T; Fujisawa T; Akasawa A; Ito K; Doi S; Yamaguchi K; Katsunuma T; Kurihara K; Kondo N; Sugai K; Nambu M; Hoshioka A; Yoshihara S; Sato N; Seko N; Nishima S
    Allergol Int; 2015 Oct; 64(4):364-70. PubMed ID: 26433533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IgE-Related Chronic Diseases and Anti-IgE-Based Treatments.
    Navinés-Ferrer A; Serrano-Candelas E; Molina-Molina GJ; Martín M
    J Immunol Res; 2016; 2016():8163803. PubMed ID: 28097159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omalizumab in asthma: an update on recent developments.
    Humbert M; Busse W; Hanania NA; Lowe PJ; Canvin J; Erpenbeck VJ; Holgate S
    J Allergy Clin Immunol Pract; 2014; 2(5):525-36.e1. PubMed ID: 25213045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of anti-IgE therapy beyond allergic asthma.
    Stokes JR; Casale TB
    J Allergy Clin Immunol Pract; 2015; 3(2):162-6. PubMed ID: 25609342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of omalizumab in children and adolescents with moderate-to-severe asthma: A systematic literature review.
    Corren J; Kavati A; Ortiz B; Colby JA; Ruiz K; Maiese BA; Cadarette SM; Panettieri RA
    Allergy Asthma Proc; 2017 Jul; 38(4):250-263. PubMed ID: 28631599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics, pharmacodynamics and clinical efficacy of omalizumab for the treatment of asthma.
    Luu M; Bardou M; Bonniaud P; Goirand F
    Expert Opin Drug Metab Toxicol; 2016 Dec; 12(12):1503-1511. PubMed ID: 27748630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Omalizumab in children with severe allergic disease: a case series.
    Crisafulli G; Caminiti L; Chiera F; Arasi S; Salzano G; Panasiti I; Barbalace A; Pajno GB
    Ital J Pediatr; 2019 Jan; 45(1):13. PubMed ID: 30642367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omalizumab as add-on therapy to inhaled steroids for asthma.
    Hadj Tahar A
    Issues Emerg Health Technol; 2004 Jun; (58):1-4. PubMed ID: 15455487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction of the total IgE level by omalizumab in children and adolescents.
    Steiss JO; Strohner P; Zimmer KP; Lindemann H
    J Asthma; 2008 Apr; 45(3):233-6. PubMed ID: 18415832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma.
    Lanier B; Bridges T; Kulus M; Taylor AF; Berhane I; Vidaurre CF
    J Allergy Clin Immunol; 2009 Dec; 124(6):1210-6. PubMed ID: 19910033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-reported outcomes in moderate-to-severe allergic asthmatics treated with omalizumab: a systematic literature review of randomized controlled trials.
    Corren J; Kavati A; Ortiz B; Vegesna A; Colby JA; Ruiz K; Panettieri RA
    Curr Med Res Opin; 2018 Jan; 34(1):65-80. PubMed ID: 29057669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Omalizumab in children with uncontrolled asthma: a real-life study carried out in Colombia].
    Morales-Múnera O; Pedraza Á; Niño-Serna L
    Rev Alerg Mex; 2018; 65(3):222-232. PubMed ID: 30176200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel targets of omalizumab in asthma.
    Sattler C; Garcia G; Humbert M
    Curr Opin Pulm Med; 2017 Jan; 23(1):56-61. PubMed ID: 27798419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Omalizumab therapy for children and adolescents with severe allergic asthma.
    Romano C
    Expert Rev Clin Immunol; 2015; 11(12):1309-19. PubMed ID: 26312385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Four-year follow-up in children with moderate/severe uncontrolled asthma after withdrawal of a 1-year omalizumab treatment.
    Baena-Cagnani CE; Teijeiro A; Canonica GW
    Curr Opin Allergy Clin Immunol; 2015 Jun; 15(3):267-71. PubMed ID: 25899697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of omalizumab for the management of severe asthma.
    Lin CH; Cheng SL
    Drug Des Devel Ther; 2016; 10():2369-78. PubMed ID: 27528798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.